您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > ML349
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ML349
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ML349图片
CAS NO:890819-86-0
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件


Name: ML349
CAS#: 890819-86-0
Chemical Formula: C23H24N2O4S2
Exact Mass: 456.1177
Molecular Weight: 456.575
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Technical InformationSynonym: ML-349; ML349; ML 349.
Chemical Name: (5,5-dioxido-3a,9b-dihydro-4H-thieno[3,2-c]thiochromen-2-yl)(4-(4-methoxyphenyl)piperazin-1-yl)methanone
InChi Key: JIFSCAIWCCQTRF-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H24N2O4S2/c1-29-18-8-6-17(7-9-18)24-10-12-25(13-11-24)23(26)20-14-16-15-31(27,28)21-5-3-2-4-19(21)22(16)30-20/h2-9,14,16,22H,10-13,15H2,1H3
SMILES Code: COC1=CC=C(N2CCN(C(C3=CC4C(C(C=CC=C5)=C5S(C4)(=O)=O)S3)=O)CC2)C=C1
实验参考方法


Target

Ki: 120 nM (APT-2)[1] IC50: 144 nM (LYPLA2)[2]

In VitroML349 is an inhibitor of acyl protein thioesterase 1 and 2 (APT-1 and APT-2) with Kis of>10000 and 120±20 nM, respectively[1]. ML349 is also an inhibitor of both LYPLA1 and LYPLA2 with IC50s of>3000 and 144 nM, respectivley[2]. ML348 and ML349 do not decrease cell viability, but they lead to a slight activation of AKT in NRAS mutant cells[3].
Cell Assay
Cells are plated in 96-well plates with a density of 4000 to 8000 cells per well and incubated for 24 h at 37°C with 5% CO2. Then cells are treated with increasing drug (including ML349) concentrations and their combinations. Cell viability is measured with the cell viability assay according to the manufacturer's protocol.
Reference

[1]. Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2). ACS Chem Biol. 2016 Dec 16;11(12):3374-3382.

[2]. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2).

[3]. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306.